Search Results - "LEVIN, Jeremey"

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy by HERRSTEDT, Jørn, APORNWIRAT, Wichit, GRUNBERG, Steven M, SHAHARYAR, Ahmed, AZIZ, Zeba, ROILA, Fausto, VAN BELLE, Simon, RUSSO, Mark W, LEVIN, Jeremey, RANGANATHAN, Salabha, GUCKERT, Mary

“…The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for…”
Get full text

Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer by Schilsky, R. L.

Get full text

Multicenter Phase II Study of a 28-Day Regimen of Orally Administered Eniluracil and Fluorouracil in the Treatment of Patients With Anthracycline- and Taxane-Resistant Advanced Breast Cancer by Rivera, E.

Get full text

Multicenter Phase II Study to Evaluate a 28-Day Regimen of Oral Fluorouracil Plus Eniluracil in the Treatment of Patients With Previously Untreated Metastatic Colorectal Cancer by MANI, S, HOCHSTER, H, HOHNEKER, J, SCHILSKY, R. L, LOKICH, J, BECK, T, CHEVLEN, E. M, O'ROURKE, M. A, WEAVER, C. H, BELL, W. N, WHITE, R, MCGUIRT, C, LEVIN, J

“…To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer. In this…”
Get full text

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study by Hesketh, Paul J., Wright, Oliver, Rosati, Gerardo, Russo, Mark, Levin, Jeremey, Lane, Stephen, Moiseyenko, Vladimir, Dube, Pierre, Kopp, Mikhail, Makhson, Anatoly

“…Purpose The primary objective was to determine if a single dose of casopitant 90 mg added to ondansetron and dexamethasone would improve the control of…”
Get full text

Phase 2 trial results with the novel neurokinin‐1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy by Arpornwirat, Wichit, Albert, Istvan, Hansen, Vincent L., Levin, Jeremey, Bandekar, Rajesh R., Grunberg, Steven M.

“…BACKGROUND: This randomized, double‐blind, dose‐ranging, placebo‐controlled, phase 2 trial evaluated the neurokinin‐1 receptor antagonist casopitant mesylate…”
Get full text

Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Postdischarge Nausea and Vomiting in High-risk Patients by SINGLA, Neil K, SINGLA, Sonia K, CHUNG, Frances, KUTSOGIANNIS, Demetrios J, BLACKBURN, Linda, LANE, Stephen R, LEVIN, Jeremey, JOHNSON, Brendan, PERGOLIZZI, Joseph V

“…In recent years, there has been an increased interest in using a multimodal approach with combined agents to treat postoperative nausea and vomiting. This…”
Get full text

Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study by Ramlau, Rodryg, Jassem, Jacek, Papai-Szekely, Zsolt, Chabot, Pierre, Legenne, Philippe, Levin, Jeremey, Sherlock, Jadwiga, Lane, Stephen R., Brennan, John J, Sessa, Tracey, Wissel, Paul Stephen, Bonomi, Philip

“…Abstract only 2031 Background: Brain metastases from NSCLC occur in ~ 20% of pts and if untreated are associated with a 1 to 2 month overall survival (OS)…”
Get full text

Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis by Armstrong, Deborah K., Spriggs, David, Levin, Jeremey, Poulin, Ruth, Lane, Stephen

“…Learning Objectives After completing this course, the reader will be able to: Explain the approved indications and treatment schedules for topotecan. Describe…”
Get full text

Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status by Treat, Joseph, Huang, Chao Hui, Lane, Stephen R., Levin, Jeremey

“…Learning Objectives After completing this course, the reader will be able to: Describe the hematologic safety profile of topotecan in patients with relapsed…”
Get full text

Clinical development of eniluracil/fluorouracil : an oral treatment for patients with solid tumors: The Oral Fluorinated Pyrimidines by LEVIN, Jeremey, HOHNEKER, John

Get full text

Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors by Levin, J, Hohneker, J

“…Eniluracil (776C85, GW776) inactivates dihydropyrimidine dehydrogenase (DPD), the principal enzyme of 5-fluorouracil (5-FU) catabolism. Inactivation of DPD…”
Get full text

Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study by Altorjay, Aron, Melson, Timothy, Chinachoit, Thitima, Kett, Attila, Aqua, Keith, Levin, Jeremey, Blackburn, Linda M, Lane, Steve, Pergolizzi, Jr, Joseph V

“…Postoperative nausea and vomiting (PONV) are associated with a variety of complications. Neurokinin subtype 1 receptor antagonists have antiemetic activity in…”
Get more information

Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer by RIVERA, Edgardo, SUTTON, Linda, COLWELL, Bruce, GRAHAM, Mark, FRYE, Debra, SOMERVILLE, Matt, CONKLIN, Heather S, MCGUIRT, Chip, LEVIN, Jeremey, HORTOBAGYI, Gabriel N

“…Eniluracil (776C85), a potent inactivator of dihydropyrimidine dehydrogenase, allows fluorouracil (5-FU) to be administered orally on a schedule that simulates…”
Get full text

Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer by SCHILSKY, Richard L, LEVIN, Jeremey, MCGUIRT, Paul V, PAZDUR, Richard, WEST, William H, WONG, Alfred, COLWELL, Bruce, THIRLWELL, Michael P, ANSARI, Rafat H, BELL, William N, WHITE, Robin L, YATES, Barbara B

“…To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with…”
Get full text

A Phase I Trial of Weekly Paclitaxel Plus Prolonged Oral Eniluracil/5‐Fluorouracil in Patients with Refractory Malignancies by Jones, Suzanne F., Greco, F. Anthony, Hainsworth, John D., Patton, Jeffrey W., Barton, John H., Willcutt, Noel T., Baker, Margaret N., McGuirt, Paul V., Levin, Jeremey, Burris, Howard A.

“…Purpose. This phase I study was conducted to determine the dose‐limiting toxicity (DLT), maximum‐tolerated doses, and recommended phase II doses of the…”
Get full text

CARCINOGEN METABOLISM AND DNA DAMAGE IN THE RODENT PANCREAS by LEVIN, JEREMEY

“…This study was designed to investigate metabolic activation and DNA damaging activity of a series of N-nitrosamines that are carcinogenic in the Syrian golden…”
Get full text

DNA damage in isolated hamster and rat pancreas cells by pancreatic carcinogens by Levin, J, Phillips, B, Iqbal, Z M

“…N-Nitrosobis(2-oxopropyl)amine (BOP), N-nitrosobis(2-hydroxypropyl)-amine (BHP) and N-nitroso(2-hydroxypropyl-2-oxopropyl)amine (HPOP) are pancreatic…”
Get more information